November 25, 2014
MSD K.K. said that it filed a new drug application in Japan on November 21 for its investigational once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin for the treatment of type 2 diabetes. In a PIII clinical trial in the country, omarigliptin...read more